article thumbnail

Opinion: Compounding pharmacies offer a fix for shortages of essential drugs

STAT

At the urging of the Alliance for Pharmacy Compounding, the trade association I lead, the Food and Drug Administration in April 2020 issued temporary guidance allowing traditional compounding pharmacies, within tight regulatory guardrails, to prepare 13 Covid drugs from pure ingredients to meet hospitals’ urgent need.

article thumbnail

Elevating Sterile Compounding Accuracy

Omnicell

Terri Albarano, PharmD Director, Autonomous Pharmacy, Omnicell Sterile compounding safety is one of the biggest challenges for the pharmacy supply chain. Health systems are expected to compound IV preparations with increasingly complex regulations, rising drug costs, and supply disruptions. Injectable medications cause 1.2

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Driving Safety and Savings Through System-Wide Sterile Compounding Automation

Omnicell

David Webster Director of Acute Care Pharmacy Operations, University of Rochester Medical Center Sterile compounding is one of the most high risk, high cost areas of medication management. Manual compounding is fraught with error, studies indicating 1 in 10 IVs are not prepared according to guidelines.

article thumbnail

DEA Reaffirms Synthetic THC Compounds Are Schedule I Controlled Substances

The FDA Law Blog

THC acetate esters are different than delta-9-THC, the psychoactive compound found naturally in the cannabis plant. Dr. Boos explained that delta-9-THCO and delta-8-THCO have similar chemical structures and pharmacological activities as compounds in the cannabis plant so they fall within the definition of THC. Terrence L. Boos, Ph.D.,

article thumbnail

Welcome to Opening Day of Omnicell Illuminate 2020

Omnicell

Randall Lipps Chairman, President, CEO, and Founder, Omnicell Today, I was excited to join thousands of registrants representing pharmacy, nursing, informatics, and healthcare leaders for the launch of Omnicell Illuminate 2020 , one of the year’s biggest digital events dedicated to technology-driven medication management.

article thumbnail

2020 review – Pharma’s progress outside of COVID-19

pharmaphorum

2020 also saw some of the first “tumour agnostic” cancer drugs get to market, with Bayer’s Vitravki (larotrectinib) getting funding in the UK for tumours with confirmed neurotrophic tyrosine receptor kinase (NTRK) gene fusions.”. Merck & Co is already a major player in immunotherapy with its Keytruda (pembrolizumab) and spent $2.75

FDA 96
article thumbnail

Endometriosis market projected to grow at a CAGR of 10% between 2020 and 2030

Pharmaceutical Technology

The endometriosis market is expected to grow from $1.05bn in 2020 to $2.72bn in 2030 at a compound annual growth rate (CAGR) of 10.0% The figure below summarises the endometriosis market growth across the 7MM from 2020 to 2030. At the end of 2030, the US will contribute approximately 81.3% of 7MM sales.